ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 584

The Effect Of Ramipril On Endothelial Function and Endothelial Progenitor Cells In Patients With Systemic Lupus Erythematosus

Emilia I. Sato1, Luiz Samuel G. Machado2 and Ana Cecilia Machado3, 1Rheumatology Div/Dept of Med, Escola Paulista de Medicina - Universidade Federal de São Paulo, Sao Paulo, Brazil, 2Rheumatology, Universidade Federal de São Paulo, São Paulo, Brazil, 3Medicina, Universidade Federal de São Paulo, São Paulo, Brazil

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Cardiovascular disease, endothelial cells and systemic lupus erythematosus (SLE)

  • Tweet
  • Email
  • Print
Session Information

Session Title: Systemic Lupus Erythematosus - Clinical Aspects I - Renal, Malignancy, Cardiovascular Disease

Session Type: Abstract Submissions (ACR)

Background/Purpose: Cardiovascular diseases (CVD) are one of major causes of morbidity and mortality in SLE patients. Traditional cardiovascular risk factors and disease intrinsic factors contribute to this pathogenesis.  Endothelial progenitors cells (EPCs) are involved in the re-endothelialization of damaged vessels and contribute to endothelial dysfunction. SLE patients have endothelial dysfunction and have fewer EPCs than healthy controls. Angiotensin converting enzyme (ACE) inhibitors such as ramipril in patients with coronary heart disease improve endothelial function and reduced CV morbidity and mortality. The Objective of the study was to evaluate the effect of ramipril on endothelial function as well on the number and function of EPCs in SLE patients

Methods:

Prospective, randomized, controlled trial. Female patients with SLE (ACR criteria) over 18 years of age, with stable medications were invited to participate. Risk factors for CVD were exclusion criteria.  SLE patients who signed consent form were randomized into two groups: intervention group (IG) and control group (CG). The IG used ramipril 10mg/day for 12 weeks. All patients were assessed at baseline and after 12 weeks, with a physical exam and also collected blood sample.  Disease activity was assessed by SLEDAI score  and EPCs were evaluated by culture using Endocult (Stemcell Technologies, USA), according appropriate protocol and by flow cytometry using anti-KDR-APC (R&D Systems, USA), anti-CD34-FITC (Southern Biotech Assoc Inc, USA), anti-CD133-PE (Miltenyi Biotec, USA) and  7AAD (Southern Biotech Assoc. Inc, USA).  The assessment of endothelial function was done through an ultrasonography of the brachial artery and flow mediated dilation (FMD), according the established protocol.  Student t test was used for normally distributed variables, Fisher exact test for categorical variables and ANOVA for repeated measures. Intent to treat analysis was done. P < 0.05 was considered significant.

Results:

37  SLE patients were evaluated , 18 in IG and 19 in CG.

At baseline, there was no difference between IG and CG regarding  the average of age,  disease duration, arterial pressure, LDL cholesterol, BMI,  FMD,  use of immunosuppressive drug and SLEDAI score. We found a significant increase on  FMD in IG (6.17±4.18% vs 11.14±5.4%, p<0.001), without difference in CG  ( 5.37±3.91% vs  5, 02±3.62%, p=0.630), comparing first (baseline) and  final (12 weeks) assessment.  We also found a increase in the number of colony forming units (CFU) of EPCs in IG  (21.3±10.4 vs 31.6±8.5, p<0.001), without difference in CG (24.8±13.5 vs 25.8±11.6, p=0.714).  There was no difference concerning EPCs number evaluated by cytometry in IG (0.013 %±0.025 vs 0.02%±0.03 p=0.734) either in CG  (0.0175±0.024 vs 0.012%±0.016%, p=0.734)

 Conclusion: Ramipril improved endothelial function in patients with SLE  and  also increased the number of EPCs evaluated in cell culture, suggesting that the improvement of endothelial function can be due to the increase in EPCs function. ACE inhibitors should be used as a preferential drug to treat hypertension in SLE patients and may be could reduce CVD in these patients


Disclosure:

E. I. Sato,
None;

L. S. G. Machado,
None;

A. C. Machado,
None.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-effect-of-ramipril-on-endothelial-function-and-endothelial-progenitor-cells-in-patients-with-systemic-lupus-erythematosus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2022 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies